Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06862856 · ClinicalTrials.gov registry record
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
A clinical trial of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT06862856 is a study of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06862856, a study of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Positron Emission Tomography (PET)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06862856
The ClinicalTrials.gov registry entry for NCT06862856 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (60% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Tomography (PET) is the first listed.
NCT06862856 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06862856 about?
NCT06862856 is a clinical study titled "Flotufolastat F 18 PET in Men With Very Low PSA Recurrence". The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
What is the current status of trial NCT06862856?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-05-20. Estimated completion is 2026-12-01.
What conditions does trial NCT06862856 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen.
What interventions are being tested in trial NCT06862856?
The interventions under investigation include: Positron Emission Tomography (PET) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06862856?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06862856 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Prostate Cancer (Adenocarcinoma)
All registered trials for this condition
Prostate Specific Antigen
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.